310 related articles for article (PubMed ID: 28618915)
1. Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention.
Schiele F; Ecarnot F; Chopard R
Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):88-100. PubMed ID: 28618915
[TBL] [Abstract][Full Text] [Related]
2. Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact.
Bauters C; Tricot O; Lemesle G; Meurice T; Hennebert O; Farnier M; Lamblin N
Arch Cardiovasc Dis; 2018 Nov; 111(11):634-643. PubMed ID: 29198936
[TBL] [Abstract][Full Text] [Related]
3. Attainment of lipid goals and long-term mortality after coronary-artery bypass surgery.
Zafrir B; Saliba W; Jaffe R; Sliman H; Flugelman MY; Sharoni E
Eur J Prev Cardiol; 2019 Mar; 26(4):401-408. PubMed ID: 30426772
[TBL] [Abstract][Full Text] [Related]
4. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
Shapiro MD; Fazio S
Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk factor control is insufficient in young patients with coronary artery disease.
Christiansen MK; Jensen JM; Brøndberg AK; Bøtker HE; Jensen HK
Vasc Health Risk Manag; 2016; 12():219-27. PubMed ID: 27307744
[TBL] [Abstract][Full Text] [Related]
6. Lipids and antithrombotic treatment.
Agewall S
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):71. PubMed ID: 32176294
[No Abstract] [Full Text] [Related]
7. Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease.
Lettino M; Leonardi S; De Maria E; Halvorsen S
Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):61-70. PubMed ID: 28618904
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 inhibition in PAD patients - a rising star in secondary prevention?
Vasa; 2018 Feb; 47(2):157. PubMed ID: 29460708
[No Abstract] [Full Text] [Related]
9. Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease.
Gonzalez L; Helkin A; Gahtan V
Vasc Endovascular Surg; 2016 Feb; 50(2):119-35. PubMed ID: 26983668
[TBL] [Abstract][Full Text] [Related]
10. Hypolipidemic drugs in elderly subjects: Indications and limits.
Gazzola K; Vigna GB
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
12. Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study.
Bittencourt MS; Blankstein R; Blaha MJ; Sandfort V; Agatston AS; Budoff MJ; Blumenthal RS; Krumholz HM; Nasir K
Eur J Prev Cardiol; 2018 Nov; 25(17):1887-1898. PubMed ID: 30043629
[TBL] [Abstract][Full Text] [Related]
13. Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.
Ferrières J; Rouyer MV; Lautsch D; Ashton V; Ambegaonkar BM; Brudi P; Gitt AK;
Arch Cardiovasc Dis; 2017 Mar; 110(3):167-178. PubMed ID: 28209375
[TBL] [Abstract][Full Text] [Related]
14. Clinical controversies in lipid management.
Tziomalos K
Panminerva Med; 2015 Jun; 57(2):65-70. PubMed ID: 25669164
[TBL] [Abstract][Full Text] [Related]
15. Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage - A Meta-Analysis.
Judge C; Ruttledge S; Costello M; Murphy R; Loughlin E; Alvarez-Iglesias A; Ferguson J; Gorey S; Nolan A; Canavan M; O'Halloran M; O'Donnell MJ
J Stroke Cerebrovasc Dis; 2019 Jun; 28(6):1703-1709. PubMed ID: 30878368
[TBL] [Abstract][Full Text] [Related]
16. Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice.
Sinning D; Landmesser U
Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):71-76. PubMed ID: 28618905
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry.
Dyrbuś K; Osadnik T; Desperak P; Desperak A; Gąsior M; Banach M
Pharmacol Res; 2018 Jun; 132():204-210. PubMed ID: 29258913
[TBL] [Abstract][Full Text] [Related]
18. Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.
Journath G; Hambraeus K; Hagström E; Pettersson B; Löthgren M
BMC Cardiovasc Disord; 2017 Aug; 17(1):224. PubMed ID: 28814290
[TBL] [Abstract][Full Text] [Related]
19. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.
Wongcharoen W; Sutthiwutthichai S; Gunaparn S; Phrommintikul A
BMC Cardiovasc Disord; 2017 Jan; 17(1):10. PubMed ID: 28056802
[TBL] [Abstract][Full Text] [Related]
20. Lipid-lowering nutraceuticals update on scientific evidence.
Derosa G; Colletti A; Maffioli P; D'Angelo A; Lupi A; Zito GB; Mureddu GF; Raddino R; Fedele F; Cicero AFG
J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):845-859. PubMed ID: 32639326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
